De Berardis Domenico, Marini Stefano, Carano Alessandro, Lang Antonella Padovan, Cavuto Marilde, Piersanti Monica, Fornaro Michele, Perna Giampaolo, Valchera Alessandro, Mazza Monica, Iasevoli Felice, Martinotti Giovanni, Di Giannantonio Massimo
NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital, G. Mazzini, Asl 4, Teramo, Italy.
Curr Clin Pharmacol. 2013 Aug;8(3):256-64. doi: 10.2174/15748847113089990056.
Schizophrenia is a chronic, severe and recurrent brain disorder that requires continuous, long-term treatment with antipsychotic medication to minimize relapse and provide clinical benefit to patients. For patients with schizophrenia, non-adherence to medication is a major risk factor for relapse and re-hospitalization. Long-acting injectable formulations of second-generation antipsychotics (SGAs-LAIs) provide constant medication delivery and the potential for improved adherence. Currently, three drugs are available for the treatment of schizophrenia, risperidone longacting injectable, olanzapine pamoate and paliperidone palmitate. Several studies have also demonstrated efficacy and safety of such drugs in patients with acute schizophrenia. In the present paper the literature on LAI atypical antipsychotics will be reviewed and practical advice will be given concerning the use of these drugs in the clinical practice.
精神分裂症是一种慢性、严重且复发性的脑部疾病，需要使用抗精神病药物进行持续的长期治疗，以尽量减少复发并为患者带来临床益处。对于精神分裂症患者而言，不坚持服药是复发和再次住院的主要风险因素。第二代抗精神病药物长效注射剂（SGAs-LAIs）可实现持续给药，并有可能提高服药依从性。目前，有三种药物可用于治疗精神分裂症，即长效注射用利培酮、奥氮平棕榈酸酯和帕利哌酮棕榈酸酯。多项研究还证实了此类药物在急性精神分裂症患者中的疗效和安全性。本文将对长效非典型抗精神病药物的文献进行综述，并就这些药物在临床实践中的使用提供实用建议。
